Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Company’s product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting multiple biological pathways. AXA1665 is being developed as a product candidate for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. Its AXA1125 AXA1125 is being developed as an oral product candidate for the treatment of non-alcoholic steatohepatitis (NASH). The Company’s pipeline includes lead therapeutic candidates for the treatment of NASH, for the treatment of long COVID (also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19, or PASC) associated fatigue, and for the reduction in risk of recurrent OHE.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)